Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CJRB-101 + pembrolizumab
- Development stage
- Phase 2
- Lead developer
- CJ Bioscience
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
CJRB-101 + pembrolizumab is a combination therapy consisting of CJRB-101, a live biotherapeutic product, and pembrolizumab, an immune checkpoint inhibitor. This combination is being investigated for the treatment of advanced or metastatic cancers. CJRB-101 appears to work through TLR4-dependent stimulation of key immune cell populations (macrophages, CD8+ T cells, neutrophils), while pembrolizumab is a PD-1 inhibitor. The combination aims to address the unmet medical needs of low response rates and refractoriness to immune checkpoint inhibitors in certain cancer populations.
02
Targets
Beyond the preview
Go deeper on CJRB-101 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CJRB-101 + pembrolizumab.